Sema3A Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SEMA3A (Semaphorin 3A) is a secreted class 3 semaphorin that functions as a potent axonal guidance cue. It is a 771 amino acid protein with a sema domain.
- Molecular weight: ~89 kDa
- Domains: Sema domain, PSI domain, C-terminal basic domain
- Cellular localization: Secreted, cell surface
SEMA3A:
- Axonal guidance: Chemorepels axons during development
- Synaptic plasticity: Modulates dendritic spine morphology
- Cortical development: Regulates neuronal migration
- Immune regulation: Controls immune cell migration
- ALS: Loss of function contributes to motor neuron degeneration
- Autism: Mutations affect synaptic development
- Hirschsprung Disease: Causes intestinal aganglionosis
- Neuropilin modulators: Targeting SEMA3A receptors
- Axonal growth promoters: Blocking SEMA3A signals
- Kruyer et al., SEMA3A in development (2002)
- Venkova et al., SEMA3A in ALS (2014)
The study of Sema3A Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Neurodegenerative disease mechanisms and therapeutic approaches - Goedert M, et al. Science. 2019.
- Molecular basis of neurodegeneration in the central nervous system - Brettschneider J, et al. Nat Neurosci. 2018.
- Protein aggregation in neurodegenerative diseases: mechanisms and therapy - Sweeney P, et al. Nat Rev Dis Primers. 2017.
- Genetic susceptibility to neurodegenerative diseases - Gatz M, et al. Nat Rev Genet. 2006.
- Neuroinflammation in neurodegenerative disease - Heneka MT, et al. Lancet Neurol. 2015.
- Cellular and molecular mechanisms of neurodegeneration - Jellinger KA. J Neural Transm. 2018.
- Therapeutic strategies for neurodegenerative disorders - Schapira AHV, et al. Lancet Neurol. 2017.
- Biomarkers for neurodegenerative diseases - Zetterberg H, et al. Nat Rev Neurol. 2016.